Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases
(PresseBox) - Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.
Protagen CEO Stefan Müllner comments, "The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team."
PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.
Datum: 03.12.2013 - 04:00 Uhr
Sprache: Deutsch
News-ID 1288632
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Dortmund
Phone:
Kategorie:
Electronics & Semiconductors
Anmerkungen:
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases
"
steht unter der journalistisch-redaktionellen Verantwortung von
Protagen AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
